LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Progenics Pharmaceuticals, Inc. (“Progenics” or “the Company”) (NASDAQ: PGNX) for potential breaches of fiduciary duty on the part of its directors in connection with the Company’s agreement to be acquired by Lantheus Holdings, Inc.
The investigation focuses on determining if Progenics’ Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Lantheus Holdings, Inc. is underpaying for the Company.
If you are a shareholder, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at email@example.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.